Patents by Inventor Heather HALEM

Heather HALEM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY
    Publication number: 20220339239
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: June 3, 2022
    Publication date: October 27, 2022
    Inventors: Heather A. Halem, Michael Dewitt Culler, Andrew Butler
  • STORAGE STABLE SOMATOSTATIN-DOPAMINE CHIMERIC COMPOUNDS AND SALT FORMS THEREOF
    Publication number: 20210338782
    Abstract: The disclosure provides storage-stable somatostatin-dopamine chimeric analog compounds and storage-stable pharmaceutical compositions thereof for use in treating endocrine diseases and endocrine tumors.
    Type: Application
    Filed: May 14, 2021
    Publication date: November 4, 2021
    Inventors: Alfredo GROSSI, Heather HALEM, Niels SVENSTRUP, Valerie CWYNAR
  • Use of Melanocortins to Treat Insulin Sensitivity
    Publication number: 20190111105
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 18, 2019
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Use of Melanocortins to Treat Insulin Sensitivity
    Publication number: 20180303899
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: November 2, 2017
    Publication date: October 25, 2018
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Use of melanocortins to treat insulin sensitivity
    Patent number: 9827286
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 28, 2017
    Assignees: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Use of Melanocortins to Treat Insulin Sensitivity
    Publication number: 20160354429
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Use of melanocortins to treat insulin sensitivity
    Patent number: 9439943
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 13, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Use of Melanocortins to Treat Insulin Sensitivity
    Publication number: 20150366934
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 24, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Use of melanocortins to treat insulin sensitivity
    Patent number: 9155777
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: October 13, 2015
    Assignees: Ipsen Pharma S.A.S., Louisiana State University
    Inventors: Heather A. Halem, Michael Dewitt Culler, Andrew A. Butler
  • USE OF MELANOCORTINS TO TREAT DYSLIPIDEMIA
    Publication number: 20130331324
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 12, 2013
    Applicant: Ipsen Pharma, S. A. S.
    Inventors: Heather A. HALEM, Michael DeWitt CULLER
  • Use of Melanocortins to Treat Dyslipidemia
    Publication number: 20120135923
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.
    Type: Application
    Filed: July 30, 2010
    Publication date: May 31, 2012
    Applicant: IPSEN PHARMA, S.A.S.
    Inventors: Heather A. Halem, Michael DeWitt Culler
  • USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY
    Publication number: 20100311647
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: November 5, 2008
    Publication date: December 9, 2010
    Inventors: Heather A. Halem, Michael Dewitt Culler, Andrew A. Butler